Search
Naxitamab
go.drugbank.com/drugs/DB15965ApprovedInvestigational[A224604] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. … [L24454] This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies,[A224604] making
Roxadustat
go.drugbank.com/drugs/DB04847ApprovedInvestigationalIt works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels. … Roxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease.
Ropeginterferon alfa-2b
go.drugbank.com/drugs/DB15119ApprovedInvestigational[A242000, A242005] [Interferon alfa-2b] has been used for decades to treat PV but requires frequent dosing and is not tolerated by all patients. … [A242010, A242015] Ropeginterferon alfa-2b was approved by the FDA on November 12, 2021, and is currently marketed under the trademark BESREMi by PharmaEssentia Corporation.[L39170]
Prochlorperazine
go.drugbank.com/drugs/DB00433ApprovedInvestigationalVet approved[label] It mainly works by depressing the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors. … [L6637] Prochlorperazine was first developed in the 1950s [L6643] and was first approved by the FDA in 1956.
Biperiden
go.drugbank.com/drugs/DB00810ApprovedInvestigationalWithdrawnIt has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
Berahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalBerahyaluronidase alfa is a recombinant variant of human hyaluronidase designed to enhance dispersion and permeation of subcutaneously co-administered drugs. … This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications
Acetylcholine
go.drugbank.com/drugs/DB03128ApprovedInvestigationalIt is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications.
Synonyms: O-AcetylcholineBetamethasone
go.drugbank.com/drugs/DB00443ApprovedInvestigationalVet approved[A192444] It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders.
Mixtures: FITODERM TC, ACELER-COProducts: BETADERM T (BETAMETASONA0.05 % CREMA)Orlistat
go.drugbank.com/drugs/DB01083ApprovedInvestigationalObesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. … In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required.